For laboratory research use only - not for human consumption

Compound hub · GHK-Cu

Does GHK-Cu work? What published studies found

Published GHK-Cu studies do not settle whether the compound works in people. In 13 people after laser resurfacing, objective skin measures did not differ between groups. The GHK-Cu group gave higher skin-quality ratings. This was a small aftercare trial. It does not show effects in other skin settings (Miller et al., 2006).

Published 2026-10-14Updated 2026-10-17Written by Form Laboratories research team19 min read

Your skin is mending itself right now, in ways you never notice. Think of a scraped knee, a shaving nick, or the daily wear of sun and wind. Nearby cells sense the damage, call for help and rebuild the fibres that hold the surface together. This page looks at which repair outcomes published GHK-Cu studies measured.

This page is part of the GHK-Cu hub. It takes the plain question people type: does GHK-Cu work? It answers with what published studies measured, in which model, and where each result stops. It reports study results. It gives no advice on using any material.

Key facts

Key facts for Does GHK-Cu work? What published studies found
CompoundGHK-Cu, the copper(II) complex of glycyl-histidyl-lysine
Studies in a 2026 systematic review20 studies (18 preclinical, 2 randomised trials in people). The review describes them as limited by differences in method (Mokhtar et al., 2026)
Post-laser skin trial13 people completed. There was no statistically significant objective difference between groups. The questionnaire rating of skin quality was higher with GHK-Cu. This was a small post-laser aftercare trial and does not show an effect for other skin settings (Miller et al., 2006)
Eyebrow split-face trial18 healthy adults aged 18 to 40, randomised, double-blind, 12 weeks. More eyebrow hairs on the treated side. No serious adverse effects reported. This was a small eyebrow-only trial. It does not show scalp-hair effects or general safety (Bo et al., 2026)
Largest cosmetic reports named in reviews71 women and 41 women; 2002 conference abstracts, not full papers (Najafi et al., 2026)
Registered trialNCT07437586, a Phase 2 study of GHK-Cu in standard acute skin wounds in healthy adults. It is randomised, double-blind and vehicle-controlled. It is recruiting, status last verified February 2026, with no results posted (ClinicalTrials.gov, checked 14 October 2026)
Human study of weight or sleep foundNone in the PubMed searches of 14 October 2026
Main study modelsCells, rats, rabbits and mice
Aesthetic Surgery Journal 2026Archives of Facial Plastic Surgery 2006Pharmaceutics 2026Archives of Internal Medicine Research 2026Procedia of Multidisciplinary Research 2026

Evidence limits

Does GHK-Cu work? What do human studies show?

Published human studies of GHK-Cu are few and mixed. The evidence does not settle whether it works. A 2026 systematic review in Aesthetic Surgery Journal found 20 studies of GHK-Cu in beauty use. Of these, 18 were preclinical, meaning cells or animals. Two were randomised trials in people. The review described the findings as limited by differences in method and few well-designed clinical trials (Mokhtar et al., 2026). In a randomised trial, 13 people finished follow-up after laser skin resurfacing. Computer analysis and blinded evaluators found no significant difference in redness between groups. Objective evaluation found no significant difference in wrinkles or skin quality. All participants improved. The GHK-Cu group rated its skin quality higher on a questionnaire (P = 0.04). This was a small aftercare trial and does not show an effect for other skin settings (Miller et al., 2006). A 2026 review in Pharmaceutics calls the clinical evidence sparse (Mateescu et al., 2026).

Where the human record comes from matters. The largest cosmetic reports named in reviews are two 2002 conference abstracts. One tested a facial cream for 12 weeks in 71 women with mild-to-advanced sun damage. The other tested an eye cream in 41 women. A 2026 review notes that neither was published as a full peer-reviewed paper (Najafi et al., 2026). That review also reports that about 35% of the main GHK-Cu papers in its window list Loren Pickart or Anna Margolina as an author. It adds that Pickart held commercial interests in the field for decades. It says this limits how independent the evidence base is (Najafi et al., 2026).

Two more human reports sit on the record. The 2026 review names an 8-week pilot of a GHK-Cu serum against a control serum. This page did not verify the primary report or its sample details. It reports no result from that pilot (Najafi et al., 2026). The second is a randomised, double-blind, placebo-controlled split-face trial of 18 healthy adults aged 18 to 40. The abstract reports significantly more and wider eyebrow hairs on the treated side than on the placebo side, especially at week 12. No serious adverse effects or allergic reactions were reported. It was a small eyebrow-only trial and does not show scalp-hair effects or general safety (Bo et al., 2026). The table below sets the human studies side by side.

Archives of Internal Medicine Research 2026Archives of Facial Plastic Surgery 2006

Does a GHK-Cu serum actually work?

A serum label cannot tell you whether that exact serum works. Najafi's 2026 review counted 11 human papers in its search. It says eight used GHK-Cu only as a comparison. That leaves three that tested GHK-Cu itself. Those are different boxes of evidence. None of them makes every shop serum a tested product.

The comparison box means another treatment was the main test. It does not mean eight strong trials proved GHK-Cu worked. The count belongs to this review. It does not cover every paper ever published (Najafi et al., 2026).

The laser box holds a different question again. Miller's 2006 trial studied skin after laser treatment. Skin ratings from patients were higher in the GHK-Cu group. Measured skin outcomes did not differ clearly between groups. These findings cannot settle whether a serum works on intact skin.

The shop serum box needs a study of that finished formula. The ingredient name alone cannot fill that box. The sources checked here do not show results for every finished serum (checked 17 October 2026).

Three separate evidence folders labelled Tested itself, Comparison only and Finished serum. The finished-serum folder is empty.
A comparison study does not test every finished serum. The empty folder marks that missing link, rather than a measured result. Source: Najafi et al., Archives of Internal Medicine Research, 2026, DOI 10.26502/aimr.0255.
Pharmaceutical Research 2015Archives of Internal Medicine Research 2026FDA microneedling devices, 15 October 2025

Have studies tested GHK-Cu with microneedles?

Yes, but the study setting matters. Li and colleagues tested GHK-Cu with microneedles in lab skin models in 2015. Microneedles are tiny points that make small openings in skin. More material crossed the lab skin after that treatment. This measured passage through skin. It did not measure lasting changes in people. Lab passage and a human result need separate evidence.

Li's study used human skin outside the body and animal models. Its safety checks used cells and pigs. These findings do not show safety for people or for a home device (Li et al., 2015).

Najafi's 2026 review also describes small human reports that used devices. It still names a gap in larger, well-controlled human trials of microneedle delivery. Those small reports do not clearly separate GHK-Cu from the other parts of treatment.

The device record is separate again. The FDA says these devices are not approved to deliver cosmetics into skin. It also says the risks of combining devices with other products are unknown. That statement is about device use. It is not about a GHK-Cu trial (FDA device summary, checked 17 October 2026).

International Journal of Molecular Sciences 2018FEBS Letters 1988Chemistry 2011Inorganic Chemistry 2021

What does research show GHK-Cu does in the body?

GHK-Cu is the copper(II) complex of the three-amino-acid peptide glycyl-histidyl-lysine (Ufnalska et al., 2021). In cultured skin fibroblasts, the cells that make connective tissue, GHK-Cu boosted collagen making. The number of cells did not change. The abstract gives no number of cultures. This is a cell-culture result and does not show a human result (Maquart et al., 1988).

Your body handles copper with care. Chemists have mapped how Cu(II) sits in GHK. Three nitrogen atoms hold it. In the solid form, a loosely held oxygen atom from a carboxylate group takes a fourth position (Hureau et al., 2011). A 2021 lab study looked at the reaction between copper-bound GHK and glutathione. It suggests a short-lived middle step may be a missing link in copper trafficking, which is how the body hands copper between proteins. This is a lab result and does not show a human result (Ufnalska et al., 2021).

The collagen link is old. The GHK sequence sits inside the alpha 2(I) chain of type I collagen. Maquart and colleagues proposed in 1988 that protein-cutting enzymes could free the tripeptide at a wound (Maquart et al., 1988). A 2018 review quotes plasma GHK values that change with age. This page did not trace them to a primary measurement, so it reports no figure. One of the review's authors held commercial interests in the field for decades (Pickart and Margolina, 2018; Najafi et al., 2026). The GHK-Cu research guide walks through the first papers in plain English.

Veterinary Surgery 2003Journal of Vascular Surgery 1992Otolaryngology–Head and Neck Surgery 2013Journal of Orthopaedic Research 2015Journal of Clinical Investigation 1993ClinicalTrials.gov NCT07437586

What have studies found about GHK-Cu and wound healing?

In 24 rats with skin wounds that had a poor blood supply, a tripeptide-copper gel made the wound area smaller than no treatment on several days. The gel differed from its vehicle gel only on days 3 and 9. By day 13, the starting wound area had fallen by 64.5% with the gel, 45.6% with the vehicle gel and 28.2% with no treatment. This is a rat result and does not show a human effect (Canapp et al., 2003). In a trial of 86 people with venous stasis ulcers, a tripeptide-copper cream did not differ from an inert cream. Silver sulfadiazine cream reduced ulcer size against both. The abstract does not state the length of the trial (Bishop et al., 1992).

Not every animal result agrees. In irradiated rat skin flaps (13 treated and 10 control animals), GHK-Cu gel made no difference to flap blood supply, blood-vessel number or area, or VEGF staining. This is a rat result and does not show a human result (Parker et al., 2013). In 72 rats after knee-ligament repair, the GHK-Cu groups had a smaller side-to-side difference in knee looseness than the saline group at 6 weeks. There was no significant difference at 12 weeks. The authors wrote that the benefit could not last once treatment stopped. This is a rat result and does not show a human result (Fu et al., 2015).

In rat wound chambers, GHK-Cu raised collagen and glycosaminoglycan content. The rise grew with the concentration. A control tripeptide had no significant effect. The abstract gives no number of rats. This is a rat result and does not show a human result (Maquart et al., 1993). A registered human trial has no results yet. NCT07437586 is a Phase 2 study of GHK-Cu in small standard wounds in healthy adults. On 14 October 2026, ClinicalTrials.gov listed it as recruiting, with status last verified in February 2026 and no results posted.

Archives of Internal Medicine Research 2026Archives of Facial Plastic Surgery 2006International Journal of Molecular Sciences 2018Inflammation Research 2011BioImpacts 2025

What have studies found about GHK-Cu, skin collagen and wrinkles?

In cultured skin fibroblasts, GHK-Cu boosted collagen making. The abstract gives no culture count. This is a cell-culture result and does not show a human result (Maquart et al., 1988). A 2026 review names an 8-week pilot of a GHK-Cu serum against a control serum. This page did not verify the primary report or its sample details. It reports no result from that pilot (Najafi et al., 2026). In the randomised laser-resurfacing trial, 13 people finished follow-up. The groups did not differ on objective measures. The GHK-Cu group rated its skin quality higher on a questionnaire. This was a small aftercare trial and does not show an effect for other skin settings (Miller et al., 2006).

A 2018 review also describes a 12-week thigh-skin study from a 1998 pilot that this page did not open. It reports no result from that pilot (Pickart and Margolina, 2018).

Skin-permeation work adds a limit. In flow-through diffusion cells, copper from a copper-tripeptide solution crossed human skin samples. Some stayed in the skin. The abstract gives no skin-sample count. The test measures copper, not intact peptide. It does not show a human result (Hostynek et al., 2011). A 2025 review in BioImpacts found 'a surprising absence of clinical studies' of GHK-Cu and a palmitoylated GHK derivative as anti-wrinkle ingredients (Mortazavi et al., 2025).

International Journal of Molecular Sciences 2018Archives of Facial Plastic Surgery 2006

Have studies measured skin glow with GHK-Cu?

None of the study abstracts opened for this page names skin glow as a measured outcome. Human studies of GHK-Cu measured wrinkles, skin density, skin thickness, looseness and redness. One review also used the word clarity (Pickart and Margolina, 2018; Miller et al., 2006). Glow is a visual impression. None of the trial abstracts opened defines it as a measurement. The word also appears as a product name for blends. That is a separate question from what GHK-Cu itself does. The GHK-Cu and Glow page covers that.

Archives of Pharmacal Research 2007Procedia of Multidisciplinary Research 2026Annals of Dermatology 2016Journal of Cosmetic and Laser Therapy 2018Pharmaceutics 2026

What have studies found about GHK-Cu and hair growth?

The sources searched for this page did not include a controlled human study of GHK-Cu alone on scalp hair. The evidence is small. A 2007 lab study tested AHK-Cu, a related copper peptide. It made cultured human hair follicles grow longer. It also made cultured dermal papilla cells multiply. These are the cells at the base of a follicle. The abstract gives no donor or culture counts. It is a culture result and does not show a human result (Pyo et al., 2007). A 2026 split-face trial in 18 healthy adults reported significantly more eyebrow hairs on the side treated with a GHK-Cu serum than on the placebo side, especially at week 12. It was a small trial on eyebrows, not scalp hair (Bo et al., 2026).

The human hair reports cover several formulas. The first was a 6-month randomised, placebo-controlled trial of 45 men with pattern hair loss. Total hair count rose by 52.6 and 71.5 in the two groups given a complex of 5-aminolevulinic acid and GHK peptide. It rose by 9.6 with placebo. The change differed significantly from placebo in one group. Hair length and thickness did not differ among the groups. No adverse event occurred in the three groups. The abstract names no copper (Lee et al., 2016). The second was a single-arm study of 1000 people given a six-ingredient hair formula that included copper tripeptide-1. Hair-pull testing showed significantly less hair fall in 83%. Total hair count was significantly higher at 1 year (P = 0.002). It had no control group and six ingredients, so no single ingredient can be credited (Kapoor and Shome, 2018).

The related-peptide question has its own limit. A 2026 Pharmaceutics review calls the AHK-Cu evidence base thin and poorly described (Mateescu et al., 2026). The sources searched for this page did not include a study that compared AHK-Cu with GHK-Cu.

PubMed search, 14 October 2026Sports Medicine 2026Frontiers in Pharmacology 2025

What have studies found about GHK-Cu and body weight?

The search did not find a trial of GHK-Cu for weight reduction in healthy people. A 2025 mouse colitis study measured weight loss caused by disease. That is a different question. The abstract gives no group sizes, and this mouse result does not show a human result (Mao et al., 2025). A PubMed search on 14 October 2026 combined GHK, GHK-Cu, copper peptide and copper tripeptide with the terms obesity, adipose tissue, body weight and weight loss. The records reviewed did not include a trial of weight reduction in healthy people. A 2026 review in Sports Medicine covers GHK-Cu among other peptides. It says rigorous human safety data for many unapproved peptides are scarce (Mendias and Awan, 2026).

One mouse study mentions weight, but as a disease marker. In a 2025 mouse model of colitis, the abstract reports that GHK-Cu eased the weight loss that the colitis caused. The abstract gives no group sizes. It does not show a human result or weight reduction in healthy animals (Mao et al., 2025).

Aging Pathobiology and Therapeutics 2023Procedia of Multidisciplinary Research 2026Annals of Dermatology 2016

Does GHK-Cu affect sleep or cause sleepiness?

The sources searched for this page did not include a human study that tested GHK-Cu on sleep or reported sleepiness as an effect. A PubMed search on 14 October 2026 combined GHK, GHK-Cu, copper peptide and copper tripeptide with sleep, sleepiness or drowsiness. It returned 10 records. The one about GHK and sleep was a mouse study. That study used GHK, the peptide without copper. Sleep-deprived aging mice given GHK did not show the sudden learning problem seen in sleep-deprived mice given saline. GHK also prevented a rise in two inflammation-linked markers, MCP-1 and nitrotyrosine, in the hippocampus, a memory region. This mouse result measured memory after lost sleep, not sleep length. The abstract gives no group sizes, and it does not show a human result (Rosenfeld et al., 2023).

The human trial abstracts opened for this page describe adverse events in general terms. In a small split-face eyebrow trial of 18 healthy adults, the abstract reports no serious adverse effects or allergic reactions. This does not show general safety (Bo et al., 2026). In 45 men with pattern hair loss, a mixed formula named GHK and no copper. The abstract reports no adverse event in any group. This does not show the safety of GHK-Cu (Lee et al., 2016). Neither abstract lists drowsiness. An abstract is a summary. A symptom missing from it is not proof that it never happened.

Scientific Reports 2016Journal of Clinical and Aesthetic Dermatology 2018

Has GHK-Cu caused itching or skin reactions in studies?

In cultured keratinocytes (skin cells), GHK-Cu was not cytotoxic. It did not significantly change irritation-related markers. Copper chloride and copper acetate raised IL-1α, IL-8, HSPA1A and FOSL1. The abstract gives no culture count. This cell-culture test does not show a human result or an itch rate (Li et al., 2016). Among 18,918 men on a multi-drug regimen that included a copper tripeptide, 802 (4.2%) had minor complications. These included itching and redness of the scalp. The regimen's other drugs mean the itching cannot be given to the copper tripeptide (Tanaka et al., 2018).

The regimen contained other medicines and ingredients. It cannot isolate the adverse effects of the copper tripeptide (Tanaka et al., 2018). The cell study covers one cell type in a dish. It does not show a human result. Neither result is a measured itch rate for GHK-Cu alone.

Veterinary Surgery 2003Archives of Facial Plastic Surgery 2006ClinicalTrials.gov NCT07437586

How fast did results appear in GHK-Cu studies?

Studies report results at fixed check-in points. They do not report when results begin. The rat wound study traced wounds daily for 13 days (Canapp et al., 2003). The human studies above ran 8 weeks for the wrinkle trial. They ran 12 weeks for the laser-resurfacing and eyebrow trials (Najafi et al., 2026; Miller et al., 2006; Bo et al., 2026). No trial abstract opened for this page reports how soon a person first showed a change. The abstracts opened give no answer on how fast it works.

The planned wound trial keeps the same pattern. The registry entry for NCT07437586 says wounds will be photographed over 3 weeks. A follow-up visit will assess scar quality (ClinicalTrials.gov, checked 14 October 2026).

Journal of Orthopaedic Research 2015Journal of Cosmetic and Laser Therapy 2018

Do GHK-Cu effects last or become permanent?

The sources read for this page do not show permanent effects of GHK-Cu. The longest follow-up of a controlled study of GHK-Cu itself that was opened was 12 weeks (Miller et al., 2006; Bo et al., 2026). In 72 rats after knee-ligament repair, the GHK-Cu groups had a smaller side-to-side difference in knee looseness at 6 weeks. There was no significant difference at 12 weeks. The authors wrote that the benefit could not last once treatment stopped. This is a rat result and does not show a human result (Fu et al., 2015). In 1,000 people, a single-arm study of a six-ingredient hair formula reported a significantly higher total hair count at 1 year. But it had no control group and several ingredients (Kapoor and Shome, 2018).

Inflammation Research 2011BioImpacts 2025Archives of Internal Medicine Research 2026Pharmaceutics 2026

What forms of GHK-Cu did studies use, and did any study compare them?

Studies tested GHK-Cu in cream, gel, serum and liposome formulas. The sources read for this page include no human study that compared forms head to head. Lab studies compare how far the peptide travels into skin instead. In a diffusion cell, copper from a GHK tripeptide solution crossed human skin samples. The abstract gives no skin-sample count. The test measures copper, not intact peptide. It does not show a human result (Hostynek et al., 2011). A 2025 review found limited clinical evidence on GHK-Cu skin delivery (Mortazavi et al., 2025).

The form matters for another reason. A 2026 review argues that the label 'GHK-Cu' does not fix the chemical state. The metal-to-ligand ratio, the pH and the free-copper content are often not fully reported (Mateescu et al., 2026). It separates free GHK, canonical GHK-Cu and GHK-derived copper peptides. It asks that evidence from each be kept separate.

Veterinary Surgery 2003Archives of Facial Plastic Surgery 2006Journal of Clinical Investigation 1993

How do researchers tell whether GHK-Cu worked in a study?

Researchers decide with set measurements. They take them before and after, and compare them against a control group. Controlled studies keep objective measurements apart from patient-reported outcomes that were set in advance. The studies above measured wound area on traced outlines (Canapp et al., 2003). They measured redness by computer analysis and blinded evaluators (Miller et al., 2006). They measured hair count and hair width from standard photographs (Bo et al., 2026). They measured collagen content in tissue (Maquart et al., 1993). In the small post-laser aftercare trial, 13 people finished. The GHK-Cu group rated its skin quality higher (P = 0.04). Objective evaluation found no significant between-group difference in improvement in wrinkles or skin quality. The trial does not show an effect for other skin settings (Miller et al., 2006).

Endocrine Reviews 2008Inflammatory Bowel Diseases 2008Frontiers in Pharmacology 2025International Journal of Medical Sciences 2025

What do studies show about KPV and GHK-Cu together?

The sources searched for this page did not include a study that tested KPV and GHK-Cu together. KPV (lysine-proline-valine) is the last three amino acids of alpha-MSH, a 13-amino-acid hormone made in the body (Brzoska et al., 2008). In mice with chemically induced colitis, KPV led to earlier recovery, a stronger regain of body weight and fewer inflammatory changes. The abstract gives no group sizes, and this mouse result does not show a human result (Kannengiesser et al., 2008). GHK-Cu was tested in a separate mouse colitis model. Per the abstract, it eased inflammatory damage and lowered inflammatory cytokines. This is also a mouse result. The abstract gives no group sizes, and it does not show a human result (Mao et al., 2025). A 2025 review covers both tripeptides in wound healing, one after the other and not as a mixture (Adnan et al., 2025).

Pharmaceutics 2026Catalogue product record, checked 14 October 2026

Is research-use GHK-Cu the same material the studies tested?

No. The studies above examined specific formulas under trial conditions. Their results are tied to the material described in each report. Research-use reference material is a laboratory compound. It is not a medicine and is not a substitute for one. It is not for human or animal use. The published results describe what happened in those studies. They say nothing about any other material.

The catalogue lists GHK-Cu reference material as freeze-dried laboratory stock. The sample report on file is a third-party heavy-metals screen. It does not measure purity or confirm identity. The quality and verification hub explains what each laboratory document records and what it cannot show.

Comparison

Human studies of GHK-Cu, related GHK formulas and copper-peptide mixtures, as opened for this page. Size, length, result and limit are as reported. This is a table of reports, not a ranking.

Comparison: Does GHK-Cu work? What published studies found
StudyDesign, size, length, reported result and limit
Miller et al., Archives of Facial Plastic Surgery, 2006A randomised trial in 13 people who finished it, with GHK-Cu skin care after laser resurfacing and outcomes at 12 weeks. Computer analysis and blinded evaluators found no statistically significant difference in redness. Objective evaluation found no significant difference in wrinkles or skin quality. All participants improved. The questionnaire rated skin quality higher with GHK-Cu (P = 0.04). This was a small aftercare trial. It does not show effects in other settings (Miller et al., 2006).
Badenhorst et al., 2016, as described by Najafi et al., 2026A pilot of a GHK-Cu serum against a control serum over 8 weeks, known only through the 2026 review. The primary report and the human sample details were not verified for this page. No result is reported (Badenhorst et al., 2016, as described by Najafi et al., 2026).
Bo et al., Procedia of Multidisciplinary Research, 2026A randomised, double-blind, placebo-controlled split-face trial in 18 healthy adults aged 18 to 40 over 12 weeks. Significantly more and wider eyebrow hairs on the treated side, especially at week 12. No serious adverse effects or allergic reactions were reported. This was a small trial on eyebrows. It does not show scalp-hair effects or general safety (Bo et al., 2026).
Lee et al., Annals of Dermatology, 2016A randomised, placebo-controlled trial in 45 men with pattern hair loss over 6 months. It tested a complex of 5-aminolevulinic acid and GHK peptide (no copper named). Hair count rose by 52.6 and 71.5 in the two complex groups and 9.6 with placebo. The change differed significantly from placebo in one group. Hair length and thickness did not differ. No adverse event occurred in the three groups. The formula was a mixed-ingredient complex that named no copper. The result does not isolate GHK-Cu (Lee et al., 2016).
Kapoor and Shome, Journal of Cosmetic and Laser Therapy, 2018A single-arm study of 1000 people given a six-ingredient hair formula that included copper tripeptide-1, followed to 1 year. Hair-pull testing showed significantly less hair fall in 83%. Total hair count was significantly higher at 1 year. There was no control group. No single ingredient can be credited (Kapoor and Shome, 2018).
Bishop et al., Journal of Vascular Surgery, 1992A randomised, evaluator-blinded trial in 86 people with venous stasis ulcers. The abstract does not state the length. Tripeptide-copper cream did not differ from inert cream. Silver sulfadiazine cream reduced ulcer size against both (Bishop et al., 1992).

FAQ

Does topical GHK-Cu work in human studies?

The answer depends on the outcome and the study. A 2026 systematic review found 18 preclinical studies and 2 randomised trials in people. It noted differences in method and few well-designed clinical trials (Mokhtar et al., 2026). In 13 people after laser resurfacing, there was no statistically significant objective difference in redness, wrinkles or skin quality between groups. The GHK-Cu group rated its skin quality higher on a questionnaire. This was a small aftercare trial and does not show effects in other skin settings (Miller et al., 2006).

Has any study measured hair growth after GHK-Cu?

In a small eyebrow trial of 18 healthy adults, the treated side had significantly more hairs, especially at week 12. It was a small trial on eyebrows, not scalp hair (Bo et al., 2026). The sources searched for this page did not include a controlled human study of GHK-Cu alone on scalp hair. AHK-Cu made cultured human hair follicles grow longer. The abstract gives no donor or culture counts. This lab result does not show a human result (Pyo et al., 2007).

Has GHK-Cu been studied for weight loss?

A PubMed search on 14 October 2026 did not find a trial of GHK-Cu for weight reduction in healthy people. The only weight result seen was weight loss caused by disease. GHK-Cu eased it in a mouse colitis model. The abstract gives no group sizes. This mouse result does not show a human result (Mao et al., 2025).

Have studies recorded itching with GHK-Cu?

Itching and redness of the scalp were recorded among 18,918 men on a multi-drug regimen that also used finasteride, minoxidil and other ingredients. The multi-drug regimen stops anyone giving the effect to the copper tripeptide (Tanaka et al., 2018). In cultured keratinocytes (skin cells), GHK-Cu did not significantly change irritation markers. The abstract gives no culture count. This cell-culture test does not show a human result or an itch rate (Li et al., 2016).

Have human studies tested GHK-Cu by routes other than the skin surface?

The human reports read that included copper tripeptide beyond the skin surface used mixed formulas. These were the 1000-person scalp study and the 18,918-person combination-treatment report. GHK-Cu's own effect cannot be separated (Kapoor and Shome, 2018; Tanaka et al., 2018). The animal studies read were in rat wound chambers and a rat knee joint (Maquart et al., 1993; Fu et al., 2015).

Is GHK-Cu the same product as Glow?

No. GHK-Cu is one defined compound. Glow is a product name. The sources searched on 14 October 2026 did not find a study that defines it. The GHK-Cu and Glow page sets out the difference.

Citations

26 sources
  1. Mokhtar J et al. Aesthetic Surgery Journal. 2026: systematic review of GHK-Cu in aesthetic medicine.
    doi:10.1093/asj/sjag169

  2. Mateescu DM et al. Pharmaceutics. 2026;18(9):1077.
    doi:10.3390/pharmaceutics18091077

  3. Najafi N et al. Archives of Internal Medicine Research. 2026;9(3):269-293.
    doi:10.26502/aimr.0255

  4. Miller TR et al. Archives of Facial Plastic Surgery. 2006;8(4):252-259.
    doi:10.1001/archfaci.8.4.252

  5. Pickart L, Margolina A. International Journal of Molecular Sciences. 2018;19(7):1987.
    doi:10.3390/ijms19071987

  6. Maquart FX et al. Journal of Clinical Investigation. 1993;92(5):2368-2376.
    doi:10.1172/JCI116842

  7. Maquart FX et al. FEBS Letters. 1988;238(2):343-346.
    doi:10.1016/0014-5793(88)80509-X

  8. Canapp SO Jr et al. Veterinary Surgery. 2003;32(6):515-523.
    doi:10.1111/j.1532-950x.2003.00515.x

  9. Bishop JB et al. Journal of Vascular Surgery. 1992;16(2):251-257.
    doi:10.1067/mva.1992.37086

  10. Parker NP et al. Otolaryngology–Head and Neck Surgery. 2013;149(3):384-389.
    doi:10.1177/0194599813492644

  11. Fu SC et al. Journal of Orthopaedic Research. 2015;33(7):1024-1033.
    doi:10.1002/jor.22831

  12. Hostynek JJ et al. Inflammation Research. 2011;60(1):79-86.
    doi:10.1007/s00011-010-0238-9

  13. Mortazavi SM et al. BioImpacts. 2025;15:30071.
    doi:10.34172/bi.30071

  14. Pyo HK et al. Archives of Pharmacal Research. 2007;30(7):834-839.
    doi:10.1007/BF02978833

  15. Lee WJ et al. Annals of Dermatology. 2016;28(4):438-443.
    doi:10.5021/ad.2016.28.4.438

  16. Kapoor R, Shome D. Journal of Cosmetic and Laser Therapy. 2018;20(6):369-379.
    doi:10.1080/14764172.2018.1439965

  17. Li H et al. Scientific Reports. 2016;6:37664.
    doi:10.1038/srep37664

  18. Rosenfeld M et al. Aging Pathobiology and Therapeutics. 2023;5(1):33-35.
    doi:10.31491/apt.2023.03.109

  19. Mendias CL, Awan TM. Sports Medicine. 2026;56(8):1921-1935.
    doi:10.1007/s40279-026-02437-0

  20. Mao S et al. Frontiers in Pharmacology. 2025;16:1551843.
    doi:10.3389/fphar.2025.1551843

  21. Kannengiesser K et al. Inflammatory Bowel Diseases. 2008;14(3):324-331.
    doi:10.1002/ibd.20334

  22. Brzoska T et al. Endocrine Reviews. 2008;29(5):581-602.
    doi:10.1210/er.2007-0027

  23. Adnan SB et al. International Journal of Medical Sciences. 2025;22(16):4175-4200.
    doi:10.7150/ijms.118118

  24. Hureau C et al. Chemistry. 2011;17(36):10151-10160.
    doi:10.1002/chem.201100751

  25. Ufnalska I et al. Inorganic Chemistry. 2021;60(23):18048-18057.
    doi:10.1021/acs.inorgchem.1c02669

  26. Li H et al. Pharmaceutical Research. 2015;32(8):2678-2689.
    doi:10.1007/s11095-015-1652-z

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Continue

GHK-Cu reference material

Research use only: not for human or animal use.

Read the GHK-Cu research guide

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease